Video

Davos 2019 - The Future of Healthcare w/ Ken Mulvany

Feb 4, 2019
HomeNEWSVideo
Davos 2019 - The Future of Healthcare w/ Ken Mulvany
Tagged:
Opinion

Live from Davos at the World Economic Forum, CNBC’s Elizabeth Schulze hosts a fireside chat with our Founder, Ken Mulvany, discussing how BenevolentAI is disrupting the pharma industry and exploring what the future of healthcare could look like.

In 2018 BenevolentAI was named a Technology Pioneer by the World Economic Forum and participated to the World Economic Forum Annual Meeting of the New Champions, held in Tianjin, China where we discussed how using AI can help unlock the world’s most complex operating system - the human body.

Receive our latest news
Featured Posts
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
Blog
Expert-augmented computational drug discovery for rare diseases
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Follow us
More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
Drug programmescareersCOVID-19Data Diversity initiative
Contact us →
Company Registration: 09781806
Terms & Conditions
Privacy & Cookies Policy